Amgen Inc Stock Performance
| AMGN Stock | USD 269.98 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.87, which signifies possible diversification benefits within a given portfolio. Amgen returns are very sensitive to returns on the market. As the market goes up or down, Amgen is expected to follow. Amgen Inc has an expected return of -0.22%. Please make sure to confirm Amgen Inc potential upside, and the relationship between the information ratio and rate of daily change , to decide if Amgen Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Amgen Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in May 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 0.22 | Five Day Return 0.0519 | Year To Date Return (9.22) | Ten Year Return 142.18 | All Time Return 78.4 K |
Forward Dividend Yield 0.0333 | Payout Ratio 0.4697 | Last Split Factor 2:1 | Forward Dividend Rate 9 | Dividend Date 2024-06-07 |
| Amgen dividend paid on 7th of March 2024 | 03/07/2024 |
1 | CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific Collaboration with Astellas | 04/03/2024 |
2 | Biophytis to Begin Phase II Obesity Study, Stock Up | 04/09/2024 |
3 | Disposition of 2508 shares by Matthew Busch of Amgen at 235.97 subject to Rule 16b-3 | 04/12/2024 |
4 | Celltrion, Samsung Bioepis vie for Prolia biosimilar leadership | 04/15/2024 |
5 | Can This High-Yield Dividend Stock Keep Beating the SP 500 | 04/17/2024 |
6 | Eli Lillys Tirzepatide Meets Goals in Sleep Apnea Studies | 04/18/2024 |
7 | Alvotech deal could heighten biosimilarpressure on Humira | 04/19/2024 |
8 | Why Amgen Outpaced the Stock Market Today | 04/22/2024 |
9 | Financial Management Network Inc Top Holdings and 13F Report | 04/24/2024 |
10 | AstraZeneca Q1 Earnings Sales Beat Estimates, Stock Up | 04/25/2024 |
| Begin Period Cash Flow | 7.6 B | |
| Total Cashflows From Investing Activities | -26.2 B |
Amgen |
Amgen Relative Risk vs. Return Landscape
If you would invest 31,218 in Amgen Inc on January 30, 2024 and sell it today you would lose (4,220) from holding Amgen Inc or give up 13.52% of portfolio value over 90 days. Amgen Inc is currently does not generate positive expected returns and assumes 1.3952% risk (volatility on return distribution) over the 90 days horizon. In different words, 12% of stocks are less volatile than Amgen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amgen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amgen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amgen Inc, and traders can use it to determine the average amount a Amgen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1555
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AMGN |
Estimated Market Risk
| 1.4 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Amgen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amgen by adding Amgen to a well-diversified portfolio.
Amgen Fundamentals Growth
Amgen Stock prices reflect investors' perceptions of the future prospects and financial health of Amgen, and Amgen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amgen Stock performance.
| Return On Equity | 1.36 | ||||
| Return On Asset | 0.0629 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 199.17 B | ||||
| Shares Outstanding | 536.38 M | ||||
| Price To Earning | 22.74 X | ||||
| Price To Book | 22.99 X | ||||
| Price To Sales | 5.08 X | ||||
| Revenue | 28.19 B | ||||
| Gross Profit | 19.92 B | ||||
| EBITDA | 7.9 B | ||||
| Net Income | 6.72 B | ||||
| Cash And Equivalents | 11.48 B | ||||
| Cash Per Share | 21.51 X | ||||
| Total Debt | 64.61 B | ||||
| Current Ratio | 1.68 X | ||||
| Book Value Per Share | 11.64 X | ||||
| Cash Flow From Operations | 8.47 B | ||||
| Earnings Per Share | 12.50 X | ||||
| Market Capitalization | 144.81 B | ||||
| Total Asset | 97.15 B | ||||
| Retained Earnings | (26.55 B) | ||||
| Working Capital | 11.94 B | ||||
| Current Asset | 38.52 B | ||||
| Current Liabilities | 8.67 B | ||||
About Amgen Performance
To evaluate Amgen Inc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Amgen generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Amgen Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Amgen Inc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Amgen's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 411.08 | 217.06 | |
| Return On Tangible Assets | 0.15 | 0.12 | |
| Return On Capital Employed | 0.10 | 0.1 | |
| Return On Assets | 0.07 | 0.12 | |
| Return On Equity | 1.08 | 1.13 |
Things to note about Amgen Inc performance evaluation
Checking the ongoing alerts about Amgen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amgen Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amgen Inc generated a negative expected return over the last 90 days | |
| Amgen Inc has a poor financial position based on the latest SEC disclosures | |
| Over 81.0% of the company shares are held by institutions such as insurance companies | |
| On 7th of March 2024 Amgen paid $ 2.25 per share dividend to its current shareholders | |
| Latest headline from zacks.com: AstraZeneca Q1 Earnings Sales Beat Estimates, Stock Up |
- Analyzing Amgen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amgen's stock is overvalued or undervalued compared to its peers.
- Examining Amgen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amgen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amgen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amgen's stock. These opinions can provide insight into Amgen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Amgen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.52) | Dividend Share 8.52 | Earnings Share 12.5 | Revenue Per Share 52.692 | Quarterly Revenue Growth 0.198 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.